Results 141 to 150 of about 34,106 (197)
Impact of Discontinuation of Contact Precautions on Healthcare-associated Extended Spectrum β-Lactamase-Producing Escherichia coli in a Large Tertiary Care Hospital: An Interrupted Time-series Analysis. [PDF]
Musumeci S +5 more
europepmc +1 more source
A One Health view of antimicrobial resistance in North Africa: Meta-analysis of ESBL-producing Enterobacteriaceae across sectors. [PDF]
Abi O +10 more
europepmc +1 more source
Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort. [PDF]
Olivares-Navarro P +24 more
europepmc +1 more source
[ESBL – risk factors and treatment].
openaire +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Characterization of ESBL disseminating plasmids
Infectious Diseases, 2015Bacteria producing extended-spectrum β-lactamases (ESBLs) constitute a globally increasing problem that contributes to treatment complications and elevated death rates. The extremely successful dissemination by ESBL-producing Enterobacteriaceae during the latest decades is a result of the combination of mobilization, evolution and horizontal spread of ...
Alma, Brolund, Linus, Sandegren
openaire +2 more sources
Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen
Journal of Clinical Microbiology, 1996Resistance to contemporary broad-spectrum beta-lactams, mediated by extended-spectrum beta-lactamase (ESBL) enzymes, is an increasing problem worldwide. The Etest (AB Biodisk, Solna, Sweden) ESBL screen uses stable gradient technology to evaluate the MIC of ceftazidime alone compared with the MIC of ceftazidime with clavulanic acid (2 micrograms/ml) to
M G, Cormican, S A, Marshall, R N, Jones
openaire +2 more sources
Journal of Infection, 2007
This study was designed to compare cefepime exposures with microbiological outcomes in ESBL and non-ESBL infections and determine the pharmacodynamic profiles associated with successful outcome.Cefepime pharmacodynamic exposures of unbound drug [time above MIC (fT>MIC), minimal concentration over MIC (fC(min)/MIC), and area under the curve over MIC ...
Su Young, Lee +2 more
openaire +2 more sources
This study was designed to compare cefepime exposures with microbiological outcomes in ESBL and non-ESBL infections and determine the pharmacodynamic profiles associated with successful outcome.Cefepime pharmacodynamic exposures of unbound drug [time above MIC (fT>MIC), minimal concentration over MIC (fC(min)/MIC), and area under the curve over MIC ...
Su Young, Lee +2 more
openaire +2 more sources

